hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06355063, orgStudyIdInfo id: NP-PCF-037, briefTitle: CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2025-08-31, completionDateStruct date: 2025-10-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Pulse Biosciences, Inc., class: INDUSTRY, descriptionModule briefSummary: This feasibility study will be conducted to demonstrate the initial safety and effectiveness of the CellFX® nsPFA™ Cardiac Clamp in performing a box lesion around the 4 pulmonary veins as an isolated procedure or as a part of a more extensive surgical ablation set in conjunction with concomitant cardiac surgical procedure., conditionsModule conditions: Atrial Fibrillation, conditions: Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This study is a prospective, multicenter, single arm, non-randomized, feasibility study., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: CellFX® nsPFA™ Cardiac Surgery System, outcomesModule primaryOutcomes measure: Rate of acute major adverse events (MAEs), primaryOutcomes measure: Number of Participants with acute electrical isolation of the bilateral pulmonary veins and left atrial free wall., secondaryOutcomes measure: Proportion of Participants with one or more SAEs, secondaryOutcomes measure: Number of Participants with Long-Term Technical Success, eligibilityModule sex: ALL, minimumAge: 22 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Academic Medical Center, city: Amsterdam, country: Netherlands, geoPoint lat: 52.37403, lon: 4.88969, locations facility: Maastricht University Medical Center, city: Maastricht, country: Netherlands, geoPoint lat: 50.84833, lon: 5.68889, locations facility: St. Antonius Hospital, city: Nieuwegein, country: Netherlands, geoPoint lat: 52.02917, lon: 5.08056, hasResults: False
protocolSection identificationModule nctId: NCT06355050, orgStudyIdInfo id: UKJ-ultraHART, briefTitle: Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer, acronym: ultraHART, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-30, primaryCompletionDateStruct date: 2026-09-30, completionDateStruct date: 2031-09-30, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Jena University Hospital, class: OTHER, collaborators name: University Hospital Schleswig-Holstein, collaborators name: Klinikum Stuttgart, descriptionModule briefSummary: In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered with by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively., conditionsModule conditions: Prostate Cancer, conditions: Adaptive Radiotherapy, conditions: Quality of Life, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Toxicity (CTCAE v5.0), primaryOutcomes measure: Quality of Life (EPIC 26), secondaryOutcomes measure: Planning parameters, secondaryOutcomes measure: Dose constraints, secondaryOutcomes measure: Conformity indices, secondaryOutcomes measure: Quality of adaptive planning, secondaryOutcomes measure: PSA-value, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Recurrence free survival, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 120 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Radiotherapy and Radiation Oncology, Jena University Hospital, city: Jena, country: Germany, contacts name: Klaus Pietschmann, MD, role: CONTACT, email: klaus.pietschmann@med.uni-jena.de, contacts name: Georg Wurschi, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 50.92878, lon: 11.5899, hasResults: False
protocolSection identificationModule nctId: NCT06355037, orgStudyIdInfo id: B2024.1.30, briefTitle: Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-01-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy., conditionsModule conditions: Triple-negative Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Quercetin, interventions name: Dasatinib, interventions name: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum, outcomesModule primaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Progression Free Survival (PFS), secondaryOutcomes measure: Safety and treatment-related AEs, secondaryOutcomes measure: Biomarker analysis1, secondaryOutcomes measure: Biomarker analysis2, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06355024, orgStudyIdInfo id: A2024.1.30, briefTitle: Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-01-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of Inosine with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy., conditionsModule conditions: Triple-negative Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Inosine, interventions name: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum, outcomesModule primaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Progression Free Survival (PFS), secondaryOutcomes measure: Biomarker analysis1, secondaryOutcomes measure: Safety and treatment-related AEs, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06355011, orgStudyIdInfo id: 7016194, briefTitle: Total Elbow Replacement in England: Analysis of National Joint Registry and Hospital Episode Statistics Data, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-04-02, completionDateStruct date: 2024-04-02, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: University of Manchester, class: OTHER, collaborators name: The National Joint Registry, collaborators name: The Royal College of Surgeons of England, collaborators name: John Charnley Trust, collaborators name: University of Bristol, descriptionModule briefSummary: The goal of this observational registry study is to provide detailed descriptions of the patients who are receiving primary total elbow replacement surgery in England. The main questions it aims to answer are:* Who are receiving primary total elbow replacement surgery?* Where and by whom is the total elbow replacement surgery is being performed?* What the current surgical practices for total elbow replacement?Pseudonymous data from the National Joint Registry NJR of all patients with total elbow replacement will be used., conditionsModule conditions: Total Elbow Replacement, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 3891, type: ACTUAL, armsInterventionsModule interventions name: Total Elbow Replacement, outcomesModule primaryOutcomes measure: The incidence of total elbow replacement (TER) in England, secondaryOutcomes measure: Serious adverse events or re-admissions, secondaryOutcomes measure: Duration of elective wait, secondaryOutcomes measure: Post-operative duration of stay, secondaryOutcomes measure: Surgeon volume, secondaryOutcomes measure: Hospital volume, otherOutcomes measure: Patient characteristics (Age), otherOutcomes measure: Body mass index, otherOutcomes measure: Hand dominance, otherOutcomes measure: American Society of Anaesthesiologists (ASA) grade, otherOutcomes measure: Indication for total elbow replacement, otherOutcomes measure: Socioeconomic status, otherOutcomes measure: Ethnicity, otherOutcomes measure: Co-morbidities, otherOutcomes measure: Charlson Comorbidity Index, otherOutcomes measure: Implant classification, otherOutcomes measure: Fixation type, otherOutcomes measure: Implant type, otherOutcomes measure: If radial head replacement was used, otherOutcomes measure: Grade of primary surgeon, otherOutcomes measure: Funding, otherOutcomes measure: Elective admission type, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, city: Manchester, zip: M13 9PT, country: United Kingdom, geoPoint lat: 53.48095, lon: -2.23743, hasResults: False
protocolSection identificationModule nctId: NCT06354998, orgStudyIdInfo id: mRNA-1273-P401, briefTitle: A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: ModernaTX, Inc., class: INDUSTRY, descriptionModule briefSummary: To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)., conditionsModule conditions: SARS-CoV-2, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Investigational mRNA-1273.815, interventions name: Licensed Spikevax Vaccine, outcomesModule primaryOutcomes measure: Geometric Mean of Neutralizing Antibodies (nAbs) Against SARS-CoV-2-specific Strain at Day 15, secondaryOutcomes measure: Number of Participants with Serious Adverse Events (SAEs), Adverse Events (AEs) of Special Interest (AESIs), and AEs Leading to Withdrawal From the Study, secondaryOutcomes measure: Seroresponse Rate of nAb Against the SARS-CoV-2-specific Strain at Day 15, secondaryOutcomes measure: Geometric Mean Ratio of nAb Against the SARS-CoV-2-specific Strain for Investigational mRNA-1273.815 Over the Licensed Spikevax Vaccine at Day 15, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Paratus Canberra, status: RECRUITING, city: Canberra, state: Australian Capital Territory, zip: 2617, country: Australia, geoPoint lat: -35.28346, lon: 149.12807, locations facility: Holdsworth House, status: RECRUITING, city: Darlinghurst, state: New South Wales, zip: 2010, country: Australia, geoPoint lat: -33.87939, lon: 151.21925, locations facility: Paratus Brisbane, status: RECRUITING, city: Brisbane, state: Queensland, zip: 2617, country: Australia, geoPoint lat: -27.46794, lon: 153.02809, locations facility: USC Morayfield, status: NOT_YET_RECRUITING, city: Morayfield, state: Queensland, zip: 4506, country: Australia, geoPoint lat: -27.10876, lon: 152.94907, locations facility: University of the Sunshine Coast, South Bank, status: RECRUITING, city: South Brisbane, state: Queensland, zip: 4101, country: Australia, geoPoint lat: -27.48034, lon: 153.02049, locations facility: Emeritus Melbourne, status: RECRUITING, city: Camberwell, state: Victoria, zip: 3124, country: Australia, geoPoint lat: -37.84205, lon: 145.0694, locations facility: AusTrials Sunshine Hospital, status: RECRUITING, city: Melbourne, state: Victoria, zip: 3021, country: Australia, geoPoint lat: -37.814, lon: 144.96332, hasResults: False
protocolSection identificationModule nctId: NCT06354972, orgStudyIdInfo id: SASP Turin, briefTitle: Impact of SASP in the GCF on the Outcomes of Periodontal Regeneration, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-02, primaryCompletionDateStruct date: 2022-11-02, completionDateStruct date: 2024-01-02, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: University of Turin, Italy, class: OTHER, descriptionModule briefSummary: Objectives: To test the impact of clinical inflammation and molecular expression profile (senescence-associated secretory phenotype; SASP) in the gingival crevicular fluid (GCF) on the outcomes of minimally-invasive periodontal regeneration in intra-bony defects.Methods: Sites associated with intrabony defects ≥ 3 mm requiring periodontal regeneration through minimally-invasive surgical technique were included. Pre-operatively, GCF was sampled for inflammatory biomarker analysis related to SASP \[interleukin (IL)-1β, IL-6 and IL-12; matrix-metalloproteinases (MMP)-8 and -9\]. Correlation analyses and logistic regression models were performed to assess the impact of predictors on clinical and radiographic outcomes., conditionsModule conditions: Periodontal Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: Minimally invasive surgical procedure, outcomesModule primaryOutcomes measure: Clinical attachment level change, primaryOutcomes measure: Achievement of composite outcome measure, secondaryOutcomes measure: Radiographic bone level change, secondaryOutcomes measure: Probing pocket depth change, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CIR Dental School, city: Turin, zip: 10126, country: Italy, geoPoint lat: 45.07049, lon: 7.68682, hasResults: False
protocolSection identificationModule nctId: NCT06354959, orgStudyIdInfo id: 1030020, briefTitle: Prehab for Lung and Esophageal Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2026-06-01, completionDateStruct date: 2027-01-01, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Nova Scotia Health Authority, class: OTHER, collaborators name: Dalhousie University, descriptionModule briefSummary: Research indicates that individuals diagnosed with lung or esophageal cancer who enter treatment with higher functional capacities, improved body composition, and better nutrition status tend to experience better outcomes and a higher quality of life. The primary objective of a prehabilitation health coaching program is to enhance the overall health and well-being of patients before they undergo major surgery.This personalized 8-week program encompasses elements such as nutrition, smoking cessation, sleep hygiene, and movement, equipping participants with the knowledge and tools needed to adopt healthier lifestyles., conditionsModule conditions: Neoplasm of Lung, conditions: Neoplasms, conditions: Exercise, conditions: Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Prehabilitation, outcomesModule primaryOutcomes measure: Feasibility- Recruitment, primaryOutcomes measure: Feasibility- Participant fidelity, primaryOutcomes measure: Feasibility - Safety, primaryOutcomes measure: Feasibility - Retention/Attrition, primaryOutcomes measure: Feasibility - Participant Experience, primaryOutcomes measure: Feasibility- Attendance, secondaryOutcomes measure: Functional Assessment of Cancer Therapy - Lung OR Esophageal (FACT-L/ FACT- E), secondaryOutcomes measure: Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F), secondaryOutcomes measure: 5x chair stand, secondaryOutcomes measure: Stair climb test, secondaryOutcomes measure: Grip strength, secondaryOutcomes measure: Resting Heart rate, secondaryOutcomes measure: Resting blood pressure, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Victoria General Hospital, city: Halifax, state: Nova Scotia, country: Canada, contacts name: Jodi Langley, role: CONTACT, email: jodi.langley@dal.ca, geoPoint lat: 44.64533, lon: -63.57239, hasResults: False
protocolSection identificationModule nctId: NCT06354946, orgStudyIdInfo id: SCORE 4C, briefTitle: External Validation of Simplified 4C Mortality Score by Deleting CRP, acronym: 4Cs, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-01-01, primaryCompletionDateStruct date: 2022-11-30, completionDateStruct date: 2022-12-30, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: University of Monastir, class: OTHER, descriptionModule briefSummary: The (Coronavirus Clinical Characterisation Consortoum) 4C mortality score is an accessible risk stratification score developed by the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) based on eight different parameters: age, sex, number of comorbidities, respiratory rate, peripheral oxygen saturation, level of consciousness (Glasgow Coma Scale), urea or blood urea nitrogen (BUN) level, and C reactive protein (CRP). It was derived and internally validated on a large, diverse cohort within the United Kingdom but requires external validity to confirm its generalizability. A recent validation study demonstrated that the score could be simplified by deleting CRP item which is favorable to its widespread use. we aim to validate a modified 4C score., conditionsModule conditions: COVID-19 Pandemic, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1500, type: ACTUAL, outcomesModule primaryOutcomes measure: The primary outcome was all-cause in-hospital mortality rate The primary outcome was all-cause in-hospital mortality rate, secondaryOutcomes measure: Number of patients admitted to the ICU, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: EPS Fattouma Bourguiba University hospital, city: Monastir, zip: 5020, country: Tunisia, geoPoint lat: 35.77799, lon: 10.82617, hasResults: False
protocolSection identificationModule nctId: NCT06354933, orgStudyIdInfo id: DemeNSS (3785), briefTitle: Neurological Soft Signs in Neurodegenerative Dementias, acronym: DemeNSS, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-04-01, primaryCompletionDateStruct date: 2023-11-30, completionDateStruct date: 2024-02-01, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: University of Milano Bicocca, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to investigate the prevalence of Neurological Soft Signs (NSS) in various categories of dementia patients compared to matched controls. The main questions it aims to answer are:* Does the prevalence of NSS significantly differ among patients with neurodegenerative dementias compared to controls?* Are NSS associated with neuropsychiatric alterations in dementia patients?* Do NSS correlate with cognitive screening tools?* Do NSS increase over time in patients with neurodegenerative dementias?Participants will undergo assessments including:* Evaluation of NSS using the Heidelberg scale* Neuropsychiatric assessments* Cognitive screening using the Mini-Mental State Examination (MMSE) and Frontal Assessment Battery (FAB)Researchers will compare dementia groups (Alzheimer's disease, Frontotemporal dementia, Corticobasal syndrome and Lewy body dementia) to controls to determine differences in NSS prevalence. Additionally, associations between NSS and neuropsychiatric symptoms, as well as cognitive performance, will be explored., conditionsModule conditions: Alzheimer Disease, conditions: Dementia With Lewy Bodies, conditions: Frontotemporal Dementia, conditions: Corticobasal Degeneration, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 186, type: ACTUAL, armsInterventionsModule interventions name: Neurological Soft Signs, outcomesModule primaryOutcomes measure: Difference in NSS, secondaryOutcomes measure: Association between NSS and Neuropsychiatric Inventory (NPI) scores, secondaryOutcomes measure: Correlation between NSS scores and cognitive function assessed by Mini-Mental State Examination (MMSE), secondaryOutcomes measure: Correlation between NSS scores and cognitive function assessed by Frontal Assessment Battery (FAB), secondaryOutcomes measure: Longitudinal changes in NSS scores, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione IRCCS San Gerardo dei Tintori, city: Monza, state: Lombardia, zip: 20900, country: Italy, geoPoint lat: 45.58005, lon: 9.27246, hasResults: False